Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Executive Summary
Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4
You may also be interested in...
Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival
Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said
Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival
Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said
Progression-Free Survival Must Be Tied To Survival For Oncologic Approval
Progression-free survival will have to be validated as a surrogate for survival on a cancer-by-cancer basis for PFS to be considered as a valid endpoint for approval, comments by FDA and members of its Oncologic Drugs Advisory Committee suggest